BioVie Inc. Files 8-K

TL;DR

BioVie Inc. filed an 8-K on 3/11/24. Standard corporate update.

AI Summary

BioVie Inc. filed an 8-K on March 11, 2024, reporting on other events and financial statements. The company, formerly known as NanoAntibiotics, Inc., is incorporated in Nevada and operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing provides an update on BioVie Inc.'s corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This is a routine corporate filing (8-K) with no immediately apparent material adverse events or significant financial disclosures.

Key Numbers

• 001-39015 — SEC File Number (Identifies the company's filing history with the SEC.)
• 46-2510769 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• BIOVIE INC. (company) — Registrant
• NanoAntibiotics, Inc. (company) — Former Company Name
• March 11, 2024 (date) — Date of Report
• Nevada (jurisdiction) — State of Incorporation
• 680 W Nye Lane Suite 201 Carson City, NV 89703 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — tered Class A Common Stock, par value $0.0001 per share BIVI The Nasdaq Stock Marke

Filing Documents

• bivi-20240311_8k.htm (8-K) — 26KB
• bivi-20240311_8kex99z1.htm (EX-99.1) — 19KB
• 0001520138-24-000105.txt ( ) — 219KB
• bivi-20240311.xsd (EX-101.SCH) — 3KB
• bivi-20240311_lab.xml (EX-101.LAB) — 33KB
• bivi-20240311_pre.xml (EX-101.PRE) — 22KB
• bivi-20240311_8k_htm.xml (XML) — 3KB

01

Item 8.01 Other Events. On March 11, 2024, BioVie Inc. (the "Company") issued a press release announcing updates on its drug candidate pipeline and near-term clinical priorities. The Company is filing a copy of the press release, which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. In this report, forward-looking statements include, but are not limited to, the potential impact of NE3107 on cognition and function among study participants and topline data from the NE3107 trial and the Company's estimate of clinical trial progress for its product candidates. Although the Company believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to certain risks, including but are not limited to, the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair the Company's ability to pay future dividends, the Company's ability tocomplete the Company's pre-clinical or clinical studies and to obtain approval for the Company's productcandidates, the Company's ability to successfully defend potential future litigation, changes in local or national economic conditionsas well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the Securities and Exchange Commission, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. The Company does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits . Exhibit No. Description 99.1 Press Release dated March 11, 2024. 104 Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101). -1-

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 11, 2024 BIOVIE INC. By: /s/ Joanne Wendy Kim Name: Joanne Wendy Kim Title: Chief Financial Officer -2-

View Full Filing

View this 8-K filing on SEC EDGAR